| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
TD Cowen analyst Yaron Werber downgrades IO Biotech (NASDAQ:IOBT) from Buy to Hold.
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded do...
Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands...
HC Wainwright & Co. analyst Emily Bodnar downgrades IO Biotech (NASDAQ: IOBT) from Buy to Neutral.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market ...
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical tri...
FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical tri...
